Derval O'Carroll
Compliance Officer bij INFLARX N.V.
Vermogen: - $ op 31-03-2024
Actieve functies van Derval O'Carroll
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| INFLARX N.V. | Compliance Officer | 01-01-2022 | - |
| General Counsel | 01-01-2022 | - |
Loopbaan van Derval O'Carroll
Eerdere bekende functies van Derval O'Carroll
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| TRAVERE THERAPEUTICS, INC. | General Counsel | 01-12-2015 | 01-12-2017 |
| AMRYT PHARMA PLC | General Counsel | - | - |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | General Counsel | 24-01-2018 | - |
Opleiding van Derval O'Carroll
| University College Dublin | Graduate Degree |
Statistieken
Internationaal
| Verenigd Koninkrijk | 3 |
| Ierland | 2 |
| Verenigde Staten | 2 |
Operationeel
| General Counsel | 4 |
| Graduate Degree | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| TRAVERE THERAPEUTICS, INC. | Health Technology |
| INFLARX N.V. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Amryt Pharma Holdings Ltd.
Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Amryt Pharma Holdings Ltd. is a pharmaceutical company, which engages in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. Its products include Lomitapide and Metreleptin. The Lomitapide provides homozygous familial hypercholesterolemia (HoFH), and Metreleptin provides treatment for generalized lipodystrophy (GL) and partial lipodystrophy (PL). The company was founded on December 20, 2004 and is headquartered in London, the United Kingdom. | Health Technology |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland. | Health Technology |
- Beurs
- Insiders
- Derval O'Carroll
- Ervaring
